文献速递胸部肿瘤放疗放疗物理与技术

MET抑制剂卡马替尼增强MET外显子14突变及MET扩增非小细胞肺癌的放射敏感性

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-11-16

本研究在MET外显子14突变和MET扩增的非小细胞肺癌模型中,探讨MET抑制剂卡马替尼联合放疗的效应。体外克隆存活实验显示卡马替尼在两种突变型细胞系中均产生放射增敏,而MET野生型及人支气管上皮细胞系未见放射增强效应。体内实验中卡马替尼联合放疗较单药或单放疗显著延迟肿瘤生长。

要点

  • 卡马替尼在MET外显子14突变和MET扩增NSCLC细胞系中产生放射增敏。
  • MET野生型NSCLC及人支气管上皮细胞系未见放射增强效应。
  • 卡马替尼联合放疗较单放疗延长γH2AX表达,抑制DNA双链断裂修复。

核心结论

  • 以卡马替尼抑制MET可增强MET外显子14突变和MET扩增非小细胞肺癌模型中的放疗效果。

研究设计与样本

  • 体外评估卡马替尼和放疗对细胞增殖、集落形成、MET信号、凋亡及DNA损伤修复的影响。
  • 体内采用细胞系异种移植和患者来源异种移植模型评估肿瘤反应。
  • 采用免疫组化确认体外结果。

主要发现

  • 体外克隆存活实验显示卡马替尼在MET外显子14突变和MET扩增非小细胞肺癌细胞系中均产生放射增敏。
  • MET野生型非小细胞肺癌和人支气管上皮细胞系中未观察到放射增强效应。
  • 卡马替尼联合放疗仅检测到极少凋亡。
  • 卡马替尼联合放疗较单放疗延长γH2AX表达,抑制DNA双链断裂修复。
  • 体内卡马替尼联合放疗较溶剂对照、单卡马替尼或单放疗显著延迟肿瘤生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to investigate the effects of inhibiting the MET receptor with capmatinib, a potent and clinically relevant ATP-competitive tyrosine kinase inhibitor, in combination with radiation in MET exon 14-mutated and MET-amplified non-small cell lung (NSCLC) cancer models. METHODS AND MATERIALS: In vitro effects of capmatinib and radiation on cell proliferation, colony formation, MET signaling, apoptosis, and DNA damage repair were evaluated. In vivo tumor responses were assessed in cell line xenograft and patient-derived xenograft models. Immunohistochemistry was used to confirm the in vitro results. RESULTS: In vitro clonogenic survival assays demonstrated radiosensitization with capmatinib in both MET exon 14-mutated and MET-amplified NSCLC cell lines. No radiation-enhancing effect was observed in MET wild-type NSCLC and a human bronchial epithelial cell line. Minimal apoptosis was detected with the combination of capmatinib and radiation. Capmatinib plus radiation compared with radiation alone resulted in inhibition of DNA double-strand break repair, as measured by prolonged expression of γH2AX. In vivo, the combination of capmatinib and radiation significantly delayed tumor growth compared with vehicle control, capmatinib alone, or radiation alone. Immunohistochemistry indicated inhibition of phospho-MET and phospho-S6 and a decrease in Ki67 with inhibition of MET. CONCLUSIONS: Inhibition of MET with capmatinib enhances the effect of radiation in both MET exon 14-mutated and MET-amplified NSCLC models.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ramesh S, Cifci A, Javeri S, et al. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37979706. doi:10.1016/j.ijrobp.2023.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。